TheraRadar
← Back
Data updated: Jun 28, 2026

INWOOD LABS

Generics

INWOOD LABS is a generic drug manufacturer focused on Cardiovascular, Neurology, Gastroenterology.

1971
Since
14
Drugs
-
Trials
0
New Drugs (2yr)

INWOOD LABS's Key Drugs

INWOOD LABS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

INWOOD LABS's Recent FDA Approvals

New NDA/BLA approvals for INWOOD LABS over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

INWOOD LABS's Therapeutic Areas

INWOOD LABS's approved drugs and pipeline span 3 therapeutic areas, led by Cardiovascular and Neurology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 40%
2 drugs
Neurology 40%
2 drugs
Gastroenterology 20%
1 drugs

INWOOD LABS's Top Competitors

INWOOD LABS's closest competitors by therapeutic-area and drug-target overlap include VALIDUS PHARMS, WARNER CHILCOTT, and Bristol-Myers Squibb. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

INWOOD LABS Pipeline Snapshot

Active clinical trials for INWOOD LABS across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling